H
Hiroshi Maeda
Researcher at Kumamoto University
Publications - 915
Citations - 67944
Hiroshi Maeda is an academic researcher from Kumamoto University. The author has contributed to research in topics: Neocarzinostatin & Nitric oxide. The author has an hindex of 103, co-authored 893 publications receiving 63370 citations. Previous affiliations of Hiroshi Maeda include Osaka University & Okayama University.
Papers
More filters
Journal ArticleDOI
Multidrug resistance protein 2 implicates anticancer drug-resistance to sorafenib.
Yoshihiko Shibayama,Kou Nakano,Hiroshi Maeda,Miyuki Taguchi,Ryuji Ikeda,Mitsuru Sugawara,Ken Iseki,Yasuo Takeda,Katsushi Yamada +8 more
TL;DR: It is suggested that sorafenib is a substrate for MRP1, suggesting that MRP2 may implicate drug resistance to sorafinib, and sunitinib did not show alteration of inhibitory concentration of 50% cell growth and accumulation into the cells of MRp2 transfected cells.
Journal ArticleDOI
Development of a Fluorescent Indicator for the Bioimaging of Nitric Oxide
Hirotatsu Kojima,Kuniko Sakurai,Kazuya Kikuchi,Shigenori Kawahara,Yutaka Kirino,Hiroshi Nagoshi,Yasunobu Hirata,Takaaki Akaike,Hiroshi Maeda,Tetsuo Nagano +9 more
TL;DR: A fluorescent indicator for NO imaging in living cells is developed and will be significant for the functional clarification of NO in vivo.
Journal ArticleDOI
Chromatographic detection of thiols, disulfides, and thioesters with 5,5′-dithiobis(2-nitrobenzoic acid)
Journal ArticleDOI
Tumor-selective blood flow decrease induced by an angiotensin converting enzyme inhibitor, temocapril hydrochloride.
TL;DR: It is demonstrated that temocapril hydrochloride, an angiotensin converting enzyme inhibitor, decreases tumor tBF markedly in LY80 tumor, a subline of Yoshida sarcoma in the rat, without affecting the blood flow in liver, kidney, bone marrow, and brain.
Journal ArticleDOI
Antiviral and interferon-inducing activities of a new peptidomannan, KS-2, extracted from culture mycelia of Lentinus edodes.
TL;DR: In mice infected intranasally with influenza A2 (H2N2) virus, KS-2 was found to possess significant protective activities and significant antiviral activities were achieved not only by prophylactic but also chemotherapeutic administration.